secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001193125-25-245852
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes to acquire Avadel for $18.50/share plus up to $1.50 CVR; $1.23B bridge financing arranged
--------------------------------------------------------------------------------

- Cash consideration of $18.50 per Avadel share; CVR for additional $1.50 upon FDA approval of LUMRYZ and legal settlement.
- Bridge term loan of up to $1.23B from JPMorgan to fund the cash consideration and fees; margin 3% SOFR + step-up.
- Acquisition subject to Avadel shareholder vote, Irish High Court sanction, and US antitrust clearance; expected to close in Q1 2026.
- Avadel equity awards to be canceled for cash and CVRs; stock options with exercise price ≥ $18.50 cancelled for no consideration.
- Alkermes reported cash and total investments of $1.1B as of Sept 30, 2025 per investor presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/0001193125-25-245852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525245852/d946576d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-245852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer